<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004936</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067622</org_study_id>
    <secondary_id>ACRIN-6651</secondary_id>
    <secondary_id>GOG-183</secondary_id>
    <secondary_id>CA80098</secondary_id>
    <nct_id>NCT00004936</nct_id>
  </id_info>
  <brief_title>MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients</brief_title>
  <acronym>ACRIN 6651</acronym>
  <official_title>Role of Radiology in the Pretreatment Evaluation of Invasive Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>American College of Radiology Imaging Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures such as MRI or CT scans may improve the ability to detect&#xD;
      cervical cancer and determine the extent of disease.&#xD;
&#xD;
      PURPOSE: Diagnostic trial to determine the effectiveness of MRI and CT scans in evaluating&#xD;
      invasive cervical cancer before treatment of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the diagnostic performance of magnetic resonance imaging (MRI), computed&#xD;
           tomography (CT), and clinical FIGO staging in patients with invasive cervical cancer.&#xD;
&#xD;
        -  Compare the accuracy of MRI, CT, and clinical FIGO staging in the evaluation of&#xD;
           morphologic tumor prognostic factors in FIGO stage IB1 and stage IB2 and greater in&#xD;
           these patients.&#xD;
&#xD;
        -  Examine the value of imaging assessment of tumor prognostic factors (alone or in&#xD;
           combination) as predictors of recurrence within 2 years of surgery in these patients.&#xD;
&#xD;
        -  Evaluate the quality of life in the 12-month period after staging and treatment to&#xD;
           potentially change staging accuracy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo a computed tomography scan with iodinated contrast dye followed by a&#xD;
      magnetic resonance imaging scan with or without contrast comprising gadopentetate dimeglumine&#xD;
      or vice versa.&#xD;
&#xD;
      Within 6 weeks of first protocol imaging study, patients undergo one of the following&#xD;
      surgeries:&#xD;
&#xD;
        -  Laparoscopic, transabdominal, or transvaginal hysterectomy&#xD;
&#xD;
        -  Extrafascial total abdominal hysterectomy&#xD;
&#xD;
        -  Trachelectomy Quality of life is assessed at 1 and 12 months.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 465 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iodinated contrast dye</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>gadopentetate dimeglumine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive cervical cancer, including invasive squamous cell&#xD;
             carcinoma, adenocarcinoma, or adenosquamous carcinoma&#xD;
&#xD;
               -  FIGO stage IB1 with clinically visible gross lesion OR&#xD;
&#xD;
               -  FIGO stage IB2 or greater&#xD;
&#xD;
          -  Scheduled for one of the following surgeries at a participating Gynecological Oncology&#xD;
             Group center:&#xD;
&#xD;
               -  Laparoscopic, transabdominal, or transvaginal hysterectomy&#xD;
&#xD;
               -  Extrafascial total abdominal hysterectomy&#xD;
&#xD;
               -  Trachelectomy&#xD;
&#xD;
          -  Not scheduled for a loop electrosurgical excision procedure or a cone biopsy only&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac pacemakers&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No contraindication to computed tomography (CT) (e.g., history of allergy to CT&#xD;
             contrast medium)&#xD;
&#xD;
          -  No contraindication to magnetic resonance imaging (e.g., intracranial vascular clip)&#xD;
&#xD;
          -  No nonmalignant general medical or psychiatric condition that would preclude consent&#xD;
             or surgery&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for invasive cervical cancer&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior surgery for invasive cervical cancer&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior medical treatment for invasive cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedvig Hricak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola MA, Schwartz LH, Woodward P, Pannu H, Atri M, Hricak H. Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecol Oncol. 2009 Jan;112(1):95-103. doi: 10.1016/j.ygyno.2008.10.005. Epub 2008 Nov 20.</citation>
    <PMID>19019414</PMID>
  </results_reference>
  <results_reference>
    <citation>Hricak H, Gatsonis C, Coakley FV, Snyder B, Reinhold C, Schwartz LH, Woodward PJ, Pannu HK, Amendola M, Mitchell DG. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology. 2007 Nov;245(2):491-8. doi: 10.1148/radiol.2452061983.</citation>
    <PMID>17940305</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitchell DG, Snyder B, Coakley F, Reinhold C, Thomas G, Amendola M, Schwartz LH, Woodward P, Pannu H, Hricak H. Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006 Dec 20;24(36):5687-94. doi: 10.1200/JCO.2006.07.4799.</citation>
    <PMID>17179104</PMID>
  </results_reference>
  <results_reference>
    <citation>Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ 3rd, Fiorica JV, Gatsonis C. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol. 2005 Oct 20;23(30):7454-9. doi: 10.1200/JCO.2004.00.5397.</citation>
    <PMID>16234512</PMID>
  </results_reference>
  <results_reference>
    <citation>Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, Koelliker S, Siegelman ES, Brown JJ, McGhee RB Jr, Iyer R, Vitellas KM, Snyder B, Long HJ 3rd, Fiorica JV, Mitchell DG; American College of Radiology Imaging Network 6651; Gynecologic Oncology Group 183. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005 Dec 20;23(36):9329-37. doi: 10.1200/JCO.2005.02.0354.</citation>
    <PMID>16361632</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

